Zevra Therapeutics (ZVRA) Other Non Operating Income (2014 - 2026)

Zevra Therapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$7.2 million for Q1 2026.

• Quarterly Other Non Operating Income changed N/A year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144.3 million (down 5689.47% YoY) and the FY2025 annual result came in at -$133.7 million, down 2254.24% from the prior year.
• Other Non Operating Income was -$7.2 million for Q1 2026 at Zevra Therapeutics, up from -$265.9 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $135.4 million in Q2 2025 and bottomed at -$265.9 million in Q4 2025.
• A 3-year average of -$18.2 million and a median of -$5.1 million in 2024 frame the typical range for Other Non Operating Income.
• Peak annual rise in Other Non Operating Income reached 7470.08% in 2025, while the deepest fall reached 3630.87% in 2025.
• Zevra Therapeutics' Other Non Operating Income stood at $7.5 million in 2024, then tumbled by 3630.87% to -$265.9 million in 2025, then soared by 97.29% to -$7.2 million in 2026.
• Business Quant data shows ZVRA's Other Non Operating Income at -$7.2 million in Q1 2026, -$265.9 million in Q4 2025, and -$6.6 million in Q3 2025.